Ann: Progress towards clinical development of IMP761, page-16

This is a great discussion, and who knows how it will play out. As a company, adding another medicine that can hugely impact grievous illness is amazing. This little company using their LAG-3 intellectual property can change the landscape of the biggest markets in drug development. Current market capitalization could be a distance memory as data rockets the value based on potential to billions. AIPAC very well could be in the hands of oncologist in a year, which opens up all kinds of scenarios. IMP761 just increases the value, and in my opinion could be a multiple blockbuster when all is said and done.